Search research articles
Contact Us
Filters
Showing results (141-150 of 869) with videos related to
Page
of 87
Sort By:
Journal of Analytical Toxicology
|
March 1, 1995
A labetalol metabolite with analytical characteristics resembling amphetamines
R B Gilbert, P I Peng, D Wong
Biometrics
|
March 2, 2005
Two-sample tests for comparing intra-individual genetic sequence diversity between populations
Peter B Gilbert, A J Rossini, Raj Shankarappa
Journal of Biopharmaceutical Statistics
|
August 9, 2006
Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial
T Cai, P B Gilbert, S G Self
Current HIV Research
|
February 3, 2007
Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach
Fusheng Li, Peter B Gilbert, Steve G Self
Journal of the American Chemical Society
|
November 20, 2019
Catalytic, Enantioselective <i>syn-</i>Diamination of Alkenes
Zhonglin Tao, Bradley B Gilbert, Scott E Denmark
Current Opinion in HIV and AIDS
|
May 31, 2013
Sieve analysis in HIV-1 vaccine efficacy trials
Paul T Edlefsen, Peter B Gilbert, Morgane Rolland
Biostatistics (Oxford, England)
|
August 21, 2007
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
April 3, 2016
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
Peter B Gilbert, Holly E Janes, Yunda Huang
Current Opinion in HIV and AIDS
|
September 24, 2016
Modeling HIV vaccine trials of the future
Peter B Gilbert, Ying Huang, Holly E Janes
Statistics in Medicine
|
January 14, 2009
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
Peter B Gilbert, Li Qin, Steven G Self
Page
of 87
Search research articles
Search
Showing results (141-150 of 869) with videos related to
Sort By:
Page
of 87
Journal of Analytical Toxicology
|
March 1, 1995
A labetalol metabolite with analytical characteristics resembling amphetamines
R B Gilbert, P I Peng, D Wong
Biometrics
|
March 2, 2005
Two-sample tests for comparing intra-individual genetic sequence diversity between populations
Peter B Gilbert, A J Rossini, Raj Shankarappa
Journal of Biopharmaceutical Statistics
|
August 9, 2006
Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial
T Cai, P B Gilbert, S G Self
Current HIV Research
|
February 3, 2007
Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach
Fusheng Li, Peter B Gilbert, Steve G Self
Journal of the American Chemical Society
|
November 20, 2019
Catalytic, Enantioselective <i>syn-</i>Diamination of Alkenes
Zhonglin Tao, Bradley B Gilbert, Scott E Denmark
Current Opinion in HIV and AIDS
|
May 31, 2013
Sieve analysis in HIV-1 vaccine efficacy trials
Paul T Edlefsen, Peter B Gilbert, Morgane Rolland
Biostatistics (Oxford, England)
|
August 21, 2007
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
Peter B Gilbert, Ian W McKeague, Yanqing Sun
Statistics in Medicine
|
April 3, 2016
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
Peter B Gilbert, Holly E Janes, Yunda Huang
Current Opinion in HIV and AIDS
|
September 24, 2016
Modeling HIV vaccine trials of the future
Peter B Gilbert, Ying Huang, Holly E Janes
Statistics in Medicine
|
January 14, 2009
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'
Peter B Gilbert, Li Qin, Steven G Self
Page
of 87